Pharmacogenetics Newsletter

Volume 3, Issue 39, 10/18/2011

Question

How can the efficacy of riluzole (Rilutek) be affected for the treatment of amyotrophic lateral sclerosis (ALS; Lou Gehrig's disease) in patients with the genetic polymorphism, CYP1A2*1F?

Answer

Amyotrophic lateral sclerosis (ALS) or Lou Gehrig's disease, is a devastating, rapidly progressive, fatal neurodegenerative disease that affects the motor neurons in the cerebral cortex of the brain, brainstem, and spinal cord in adults 40-60 years of age.¹  Unfortunately, patients with ALS will develop...

.......To read the full answer please LOGIN or SUBSCRIBE NOW.